TY - JOUR
T1 - Neurological manifestations and outcomes in a retrospective cohort of mexican inpatients with SARS-CoV-2 pneumonia
T2 - Design of a risk profile
AU - García, Silvia
AU - Cuatepotzo-Burgos, Francisco Manuel
AU - Toledo-Lozano, Christian Gabriel
AU - Balderrama-Soto, Adriana
AU - Alcaraz-Estrada, Sofía Lizeth
AU - Montiel-López, Luis
AU - De la Vega-Bravo, Alberto Hilarión
AU - Mondragón-Terán, Paul
AU - Santosbeña-Lagunes, Maribel
AU - Escarela-Serrano, Maricela
AU - Rodríguez-Martínez, Celia Mireya
AU - Méndez-Vidrio, María Del Carmen
AU - Muñoz-López, Sandra
AU - Merino-Rajme, José Alfredo
AU - Rodríguez-Briseño, Rodrigo Alberto
AU - Cerda-Téllez, Fidel
AU - Coral-Vázquez, Ramón Mauricio
AU - Sauri-Suárez, Sergio
AU - Quiñonez-Aguilar, Sandra
AU - Pineda-Juárez, Juan Antonio
AU - Suárez-Cuenca, Juan Antonio
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - We analyzed the neurological manifestations in Mexican patients hospitalized with pneumonia due to COVID-19 and investigated the association between demographic, clinical, and bio-chemical variables and outcomes, including death. A retrospective, analytical study was conducted using the electronic records of patients hospitalized between 1 April 2020 and 30 September 2020. Records of 1040 patients were analyzed: 31.25% died and 79.42% had neurological symptoms, including headache (80.62%), anosmia (32.20%), ageusia (31.96%), myopathy (28.08%), disorientation (14.89%), encephalopathy (12.22%), neuropathy (5.4%), stroke (1.3%), seizures (1.3%), cerebral hemorrhage (1.08%), encephalitis (0.84%), central venous thrombosis (0.36%), and subarachnoid hemorrhage (0.24%). Patients also had comorbidities, such as hypertension (42.30%), diabetes mellitus (38.74%), obesity (61.34%), chronic obstructive pulmonary disease (3.17%), and asthma (2.01%). Factors associated with neurological symptoms were dyspnea, chronic obstructive pulmonary dis-ease, advanced respiratory support, prolonged hospitalization, and worsening fibrinogen levels. Factors associated with death were older age, advanced respiratory support, amine management, chronic obstructive pulmonary disease, intensive care unit management, dyspnea, disorientation, encephalopathy, hypertension, neuropathy, diabetes, male sex, three or more neurological symptoms, and obesity grade 3. In this study we designed a profile to help predict patients at higher risk of developing neurological complications and death following COVID-19 infection.
AB - We analyzed the neurological manifestations in Mexican patients hospitalized with pneumonia due to COVID-19 and investigated the association between demographic, clinical, and bio-chemical variables and outcomes, including death. A retrospective, analytical study was conducted using the electronic records of patients hospitalized between 1 April 2020 and 30 September 2020. Records of 1040 patients were analyzed: 31.25% died and 79.42% had neurological symptoms, including headache (80.62%), anosmia (32.20%), ageusia (31.96%), myopathy (28.08%), disorientation (14.89%), encephalopathy (12.22%), neuropathy (5.4%), stroke (1.3%), seizures (1.3%), cerebral hemorrhage (1.08%), encephalitis (0.84%), central venous thrombosis (0.36%), and subarachnoid hemorrhage (0.24%). Patients also had comorbidities, such as hypertension (42.30%), diabetes mellitus (38.74%), obesity (61.34%), chronic obstructive pulmonary disease (3.17%), and asthma (2.01%). Factors associated with neurological symptoms were dyspnea, chronic obstructive pulmonary dis-ease, advanced respiratory support, prolonged hospitalization, and worsening fibrinogen levels. Factors associated with death were older age, advanced respiratory support, amine management, chronic obstructive pulmonary disease, intensive care unit management, dyspnea, disorientation, encephalopathy, hypertension, neuropathy, diabetes, male sex, three or more neurological symptoms, and obesity grade 3. In this study we designed a profile to help predict patients at higher risk of developing neurological complications and death following COVID-19 infection.
KW - COVID-19
KW - Case fatality ratio
KW - Neurological symptoms
KW - Respiratory infection
KW - Risk profile
UR - http://www.scopus.com/inward/record.url?scp=85118809077&partnerID=8YFLogxK
U2 - 10.3390/healthcare9111501
DO - 10.3390/healthcare9111501
M3 - Artículo
C2 - 34828547
AN - SCOPUS:85118809077
SN - 2227-9032
VL - 9
JO - Healthcare (Switzerland)
JF - Healthcare (Switzerland)
IS - 11
M1 - 1501
ER -